abstract |
The invention relates to a new class of camptothecin analogs having a β-hydroxylactone in place of the alpha-hydroxylactone of the natural camptothecin structure, which gives the compounds superior biological activity in terms of inhibition of topoisomerase I and antitumor, antiviral and antiparasitic action . |